journal
MENU ▼
Read by QxMD icon Read
search

Pharmaceutical Patent Analyst

journal
https://www.readbyqxmd.com/read/28696180/epithelial-na-channel-inhibitors-for-the-treatment-of-cystic-fibrosis
#1
Nichola J Smith, Catherine F Solovay
The epithelial Na(+) channel (ENaC) is a key regulator of the volume of airway surface liquid (ASL) and is found in the human airway epithelium. In cystic fibrosis (CF), Na(+) hyperabsorption through ENaC, in the absence of cystic fibrosis transmembrane conductance regulator mediated anion secretion, results in the dehydration of respiratory secretions and the impairment of mucociliary clearance. The hypothesis of utilizing an ENaC blocking molecule to facilitate restoration of the airway surface liquid volume sufficiently to allow normal mucociliary clearance is of interest in the management of lung disease in CF patients...
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696178/a-cheat-sheet-to-navigate-the-complex-maze-of-pharmaceutical-exclusivities-in-europe
#2
Marta Cavero Tomas, Bo Peng
As the two leading markets for pharmaceutical and biotech companies, the USA and Europe offer incentives to stimulate drug innovation, including patent and regulatory exclusivities. These exclusivities extend periods during which companies can market their products free of generic or other competition and recoup their investment. Pharmaceutical and biotech companies should carefully assess the different types of exclusivities available when developing regulatory submissions, patent filing strategies. The authors have previously summarized the USA exclusivities in an earlier publication...
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696166/cellzdirect-gives-new-hope-for-patent-protection-for-personalized-medicine-in-the-usa
#3
Joan Ellis
No abstract text is available yet for this article.
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696157/toward-carbon-monoxide-based-therapeutics-carbon-monoxide-in-a-pill
#4
Xingyue Ji, Binghe Wang
As one of the three known gasotransmitters, carbon monoxide (CO) has demonstrated therapeutic potential against a wide range of human diseases. However, development of CO as a therapeutic agent is severely impeded, primarily due to the lack of pharmaceutically acceptable delivery forms of CO. Gaseous CO may only have limited utility under carefully controlled clinical environment. As a result, there have been efforts in developing metal-based CO-releasing molecules and organic CO-releasing molecules that require light activation...
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696148/3d-printing-of-pharmaceuticals-patent-and-regulatory-challenges
#5
James A Stones, Catherine M Jewell
No abstract text is available yet for this article.
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696142/patent-highlights-february-march-2017
#6
Hermann Am Mucke
No abstract text is available yet for this article.
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696149/immune-checkpoint-inhibitors-the-battle-of-giants
#7
Matthieu Collin
No abstract text is available yet for this article.
July 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485681/humira-recent-developments
#8
Peter Norman
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485677/january-2017-extended-scope-of-patent-term-extension-japan-is-progenerics-debiopharm-international-sa-vs-towa-pharmaceutical-co-ltd
#9
Takeshi S Komatani
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485666/are-therapeutic-antibodies-still-patentable-at-the-european-patent-office
#10
Vicki Allen, Graham Matthew Lewis
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485665/patent-highlights-december-2016-january-2017
#11
Hermann Am Mucke
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485650/intellectual-property-and-biodiversity-interplay
#12
Ravi Bhola, Shreya Dave
Potentially divergent objectives and thereby obligations under the Convention on Biodiversity and Trade-Related Aspects of Intellectual Property Rights Agreement are also reflected in respective domestic legislations in India. The review article focuses on Biological Diversity Act, 2002 vis-à-vis Patents Act, 1970 of India with intricacies involved thereunder. Authors have analyzed the obligations under these domestic legislations. The article goes on to make a few suggestions to aid effective implementation of both the statutes...
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28534435/genome-editing-technologies-and-patent-landscape-overview
#13
Fairouz Benahmed-Miniuk, Mat Kresz, Jitendra K Kanaujiya, Christopher D Southgate
Unlike with zinc finger nuclease and transcriptional activator-like effector nuclease DNA modification technologies that rely on lead proteins, developed through expensive and time-consuming processes, the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system has rapidly emerged as the most promising gene-editing technology to date for the modification of any selected DNA sequence. CRISPR is receiving tremendous fanfare due, in part, to its potential to provide a means to fundamentally alter medical genetics and especially cancer medicine...
May 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28343406/corrigendum
#14
(no author information available yet)
No abstract text is available yet for this article.
March 27, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28274178/the-consequences-of-double-examination-for-pharmaceutical-patent-applications-in-brazil
#15
Gabriela Salerno
No abstract text is available yet for this article.
March 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248151/p2x7-antagonists-for-cns-indications-recent-patent-disclosures
#16
REVIEW
Paolo Pevarello, Silvia Bovolenta, Paola Tarroni, Lorena Za, Elda Severi, Domenica Torino, Rocco Vitalone
P2X7, a ligand-gated purinergic ion channel, has been at the center of intense efforts in the pharmaceutical industry in the last 15 years due to the growing appreciation of its role in inflammation. Since 2008-2009, increased focus on CNS available compounds has led to the publication of various patents on behalf of several pharmaceutical companies. This patent review aims at analyzing the recent patent literature (2008-2016) with a particular emphasis on those patents that are thought to deal with CNS penetrant compounds on the basis of their physicochemical features, the assays described in the patents and the uses these compounds are claimed for...
March 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248129/key-points-of-the-new-spanish-patent-act
#17
Teresa Mercadal Menchaca
No abstract text is available yet for this article.
March 1, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248128/patent-highlights-october-november-2016
#18
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
March 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28248125/drug-delivery-via-porous-silicon-a-focused-patent-review
#19
REVIEW
Paulina A Kulyavtsev, Roxanne P Spencer
Although silicon is more commonly associated with computer chips than with drug delivery, with the discovery that porous silicon is a viable biocompatible material, mesoporous silicon with pores between 2 and 50 nm has been loaded with small molecule and biomolecule therapeutics and safely implanted for controlled release. As porous silicon is readily oxidized, porous silica must also be considered for drug delivery applications. Since 2010, only a limited number of US patents have been granted, primarily for ophthalmologic and immunotherapy applications, in contrast to the growing body of technical literature in this area...
March 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28201948/enbrel-and-etanercept-biosimilars-a-tale-of-two-patent-systems
#20
Peter Norman
No abstract text is available yet for this article.
February 16, 2017: Pharmaceutical Patent Analyst
journal
journal
47821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"